Abstract
Alzheimer's disease is a degenerative neurological condition that has no cure and only a few treatment options. It has a negative impact on one's cognitive and behavioural abilities. Traditional medications, such as acetylcholinesterase inhibitors, are often ineffective because they do not penetrate the blood-brain barrier. Targeted therapy strategies involving nanoparticulate drug delivery devices have been employed to improve the efficacy of Alzheimer's disease treatment. Memantine is an Alzheimer's disease medicine that has been approved for the treatment of mild to moderate symptoms. To boost memantine's action at the target region, we employed a twofold emulsion technique to generate lactoferrin (Lf) combined with biodegradable PEG-PLGA nanoparticles (NPs). The average particle size of the synthesised NPs was 162.60.5 nm, with a polydispersity index of 0.1 and a surface charge of -21.5 mV. The crystalline drug was disseminated within the PLGA matrix, according to the physicochemical characterisation of NPs. During in vitro dissolution studies, the new nanoparticulate formulation displayed a sustained release profile of memantine. The NPs were noncytotoxic to brain cell lines, and bEnd.3 cells had a greater concentration of Lf-NP than unconjugated nanoparticles. The researchers discovered that Lf-conjugated PEG-PLGA nanoparticles carrying memantine are excellent for Alzheimer's disease targeted delivery.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
